SGIOY News and Press, Shionogi & Co. Ltd. ADR From 05/15/19

Matinas BioPharma ( MTNB -0.3% ) inks a research collaboration agreement with ViiV Healthcare under which the latter will explore the use of the former's lipid nano-crystal (LNC) platform delivery technology in developing new antivirals. More news on: Matinas BioPharma Holdings, Inc....

ViiV Healthcare has submitted a New Drug Application (NDA) to the FDA seeking approval its once-per-month injectable two-drug regimen, cabotegravir and Janssen's rilpivirine, for the treatment of adults with HIV-1 infection whose viral load is suppressed and who are not resistant to either...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval for Viiv Healthcare's dolutegravir and lamivudine for the treatment of HIV-1 infection. More news on: GlaxoSmithKline plc, Pfizer Inc., Shionogi & Co., Ltd., Healthcare stocks news,...

BioDelivery Sciences International (NASDAQ: BDSI ) initiates a public offering of common stock. Price, volume and terms have yet to be announced. More news on: BioDelivery Sciences International, Inc., Shionogi & Co., Ltd., Shionogi & Co., Ltd., Healthcare stocks news, Stocks on ...

ViiV Healthcare, the HIV-focused joint venture between GlaxoSmithKline (NYSE: GSK ), Pfizer (NYSE: PFE ) and Shionogi ( OTCPK:SGIOY )  presents three year results from the SWORD 1 & 2 studies. More news on: GlaxoSmithKline plc, Pfizer Inc., Shionogi & Co., Ltd., Hea...

48-week results from two Phase 3 clinical trials, ATLAS and FLAIR, evaluating the combination of ViiV Healthcare's cabotegravir and Johnson & Johnson ( JNJ -0.6% ) unit Janssen Therapeutics' Edurant (rilpivirine), injected every four weeks, demonstrated non-inferiority (no worse t...